Revolution Medicines announced that its drug daraxonrasib has met the primary endpoint in a Phase 3 clinical trial involving previously treated pancreatic cancer patients. The treatment doubled the median overall survival to 13.2 months, compared to 6.7 months in the chemotherapy group. The company plans to seek regulatory review from the FDA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments